Angiopoietins

By Targets:	Anaplastic lymphoma kinase (ALK) (1) ANGPTL (3) Apoptosis (1) Insulin Receptor (1) MDM-2/p53 (1) Prolyl Endopeptidase (PREP) (1) Tie (4) VEGFR (3)
By Research Areas:	Cancer (7) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (5) Metabolic Disease (6)
Oligonucleotides:	Aptamers (1) Antisense Oligonucleotides (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-153497A

Vupanorsen sodium IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium	ANGPTL	Metabolic Disease
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

HY-P99510

Zansecimab LY-3127804	Tie	Inflammation/Immunology Cancer
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-100475

KYP-2047	Apoptosis MDM-2/p53 Prolyl Endopeptidase (PREP)	Cancer
KYP-2047 is a potent and BBB-penetrating prolyl-oligopeptidase (POP) inhibitor, with an K_i value of 0.023 nM. KYP-2047 reduces glioblastoma proliferation through angiogenesis and apoptosis modulation .

HY-P99194

Evinacumab REGN1500	ANGPTL Others	Cardiovascular Disease Metabolic Disease
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .

HY-153497

Vupanorsen IONIS ANGPT-L3Rx; ISIS 703802	ANGPTL	Metabolic Disease
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

HY-P10580

Vasculotide	Tie	Infection Metabolic Disease Inflammation/Immunology Cancer
Vasculotide, an angiopoietin-1 mimetic, is a Tie-2 activator and induces Tie-2 phosphorylation. Vasculotide has anti-inflammatiory effect and anti-permeability. Vasculotide ameliorates endotoxin-induced endothelial barrier dysfunction. Vasculotide promotes angiogenesis in a mouse model of diabetic ulcer. Vasculotide protects mice from vascular leakage and reduces mortality in murine abdominal sepsis. Vasculotide decreases microvascular leakage and improves microcirculatory perfusion in a rat model of hemorrhagic shock .

HY-14243

CEP-14083	Anaplastic lymphoma kinase (ALK) Insulin Receptor VEGFR Tie	Cancer
CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC₅₀ value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma .

Cat. No.	Product Name	Target	Research Area

HY-P4866

Q-Peptide	Peptides	Metabolic Disease
Q-Peptide is the angiopoietin-1 derived peptide (QHREDGS).Q-Peptide increases keratinocyte migration to improve wound healing, in diabetic mouse model. Q-Peptide accelerates wound closure .

HY-P10580

Vasculotide	Tie	Infection Metabolic Disease Inflammation/Immunology Cancer
Vasculotide, an angiopoietin-1 mimetic, is a Tie-2 activator and induces Tie-2 phosphorylation. Vasculotide has anti-inflammatiory effect and anti-permeability. Vasculotide ameliorates endotoxin-induced endothelial barrier dysfunction. Vasculotide promotes angiogenesis in a mouse model of diabetic ulcer. Vasculotide protects mice from vascular leakage and reduces mortality in murine abdominal sepsis. Vasculotide decreases microvascular leakage and improves microcirculatory perfusion in a rat model of hemorrhagic shock .

Cat. No.	Product Name	Target	Research Area

HY-P99036

Nesvacumab	Inhibitory Antibodies	Cardiovascular Disease Inflammation/Immunology Cancer
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand *Angiopoietin-2* (Ang2) with high affinity, but shows no binding to Ang1 .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99510

Zansecimab LY-3127804	Tie	Inflammation/Immunology Cancer
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-P99194

Evinacumab REGN1500	ANGPTL Inhibitory Antibodies	Cardiovascular Disease Metabolic Disease
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .

HY-P99546

Trebananib 2xCon4C; AMG 386	Inhibitory Antibodies	Inflammation/Immunology
Trebananib (2xCon4C; AMG 386) is an anti-ANGPT2?(angiopoietin 2, Ang2) monoclonal antibody .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99036

Nesvacumab	Classification of Application Fields Disease Research Fields Cancer	Others
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand *Angiopoietin-2* (Ang2) with high affinity, but shows no binding to Ang1 .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	Classification of Application Fields Disease Research Fields Cancer	VEGFR Tie
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99510

Zansecimab LY-3127804	Classification of Application Fields Disease Research Fields Cancer	Tie
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation .

Cat. No.	Product Name		Classification

HY-153497A

Vupanorsen sodium IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium		Antisense Oligonucleotides
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

HY-153497

Vupanorsen IONIS ANGPT-L3Rx; ISIS 703802		Antisense Oligonucleotides
Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

HY-160043

AL6 aptamer sodium		Aptamers
AL6 aptamer sodium is a short-chain nucleic acid aptamer chemically synthesized in vitro. AL6 aptamer sodium specifically targets Angiopoietin (Ang) for the specific detection of Ang. The AL6 aptamer binds to Ang, causing the rotational motion of the fluorophore on the AL6 aptamer to become slower. The concentration of Ang in the test solution can be quantified by detecting the anisotropy of AL6 aptamer/Ang .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Name
Email *

	Sorry, but the email address you supplied was invalid.

Angiopoietins

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products